Hansa Biopharma AB
(OSTO:HNSA)
kr
40.5
3 (8%)
Market Cap: 2.66 Bil
Enterprise Value: 3.06 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 77/100 Hansa Biopharma AB at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019 / 05:30PM GMT
Release Date Price:
kr140.7
(-3.76%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. Let's go ahead and get started. So hi, everyone. Thanks for being here. My name is Vikram Purohit. I'm one of the biotech analysts here at Morgan Stanley. And before we start our chat with Hansa, I just need to let everyone know that for all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, all of those appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures, or they're available at the registration desk. So with that, happy to have with me on the stage Hansa Biopharma CEO Søren Tulstrup. Welcome.
SÃ;ren Tulstrup;publ;President;CEO
Hansa Biopharma AB
¸ - ()-&
Thank you.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Before we get into program and a company-specific Q&A, perhaps it's a good
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot